Current models treat senescent cell dysfunction as a gradual decline. The evidence suggests a sharper transition governed by a specific metabolic sensor. Hypothesis: A cell-autonomous NAMPT activity threshold acts as a metabolic timer; when intracellular NAMPT (and thus NAD+) falls below this threshold, it triggers an irreversible, feed-forward switch from a transient, adaptive SASP to a chronic, pro-inflammatory MiDAS-like state, independent of initial senescence trigger.

This reframes the "breakdown" not as mere decay, but as a programmed metabolic checkpoint failure. The research shows NAD+ metabolism governs SASP via NF-κB [https://doi.org/10.1038/s41556-019-0287-4] and that mitochondrial dysfunction creates a distinct MiDAS state [https://doi.org/10.1016/j.cmet.2015.11.011]. The novel mechanistic link is that chronically declining NAMPT activity directly de-represses a specific transcriptional program (potentially involving HIF-1α stabilization under pseudo-hypoxic conditions from ETC inefficiency) that locks the cell into a pro-inflammatory, growth-suppressive state. This creates a bistable system: senescent cells are either in a NAMPT-high "negotiator" state (secretion of repair factors like PDGF-AA [https://doi.org/10.1016/j.devcel.2014.11.011]) or a NAMPT-low "detonator" state (dominated by chronic inflammation and tissue dysfunction).

Key Predictions & Testability:

1. Quantitative Threshold: Senescent cells in culture or tissue will show a bimodal distribution of NAMPT activity/immunofluorescence. Cells below a discrete threshold will exhibit a fundamentally different secretory profile (e.g., high IL-6/IL-8, low PDGF-AA) compared to those above it, even at similar days post-senescence induction.
2. Intervention Specificity: Restoring NAD+ via NAMPT overexpression in low-NAMPT senescent cells should revert SASP to a pro-repair phenotype. Simple NAD+ precursor (e.g., NR, NMN) supplementation might be ineffective if the NAMPT enzyme itself is rate-limiting or if downstream epigenetic changes are already cemented.
3. Temporal Dynamics in Vivo: In wound models, the ratio of NAMPT-high to NAMPT-low senescent cells should shift dramatically at a specific timepoint preceding healing failure. Pre-emptive NAMPT support (local delivery) should extend the adaptive phase and improve outcomes, while late-stage senolytic clearance should also show benefit, confirming the pathology resides in the NAMPT-low population.

This model explains why senolytics can be beneficial—they remove the pathological NAMPT-low cells—but also why timing matters. Eliminating NAMPT-high cells early might remove necessary signaling hubs, triggering compensatory hyperplasia or fibrosis. The hypothesis predicts that optimal therapy requires either a) sustaining the adaptive NAMPT-high state during acute injury or b) selectively targeting NAMPT-low cells in chronic settings. It moves the field from a blanket "senescent cells are bad" to a metabolic state-specific intervention strategy.